Health News

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Read more

Filed under: Pharmacy News
Tags: DNA, Drug, Hepatitis, Pharmacy

Related posts

• FDA Approves Most Comprehensive System To Test Donated Blood For HIV, Hepatitis B & Hepatitis C (0)
  The United States Food & Drug Administration (FDA) approved a new nucleic acid test from Roche to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay. The test, called the cobas TaqScreen MPX Test for use on the cobas s 201 system, is a [...]
  
  
• ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Read more [tags] Pharmacy News [/tags]
  
  
• Vertex submits NDA for telaprevir for treating hepatitis C (0)
  Vertex Pharmaceuticals Incorporated announced today that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C. Read more [tags] Pharmacy News [/tags]
  
  
• Vertex receives FDA approval for INCIVEK to treat hepatitis C (0)
  Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). Read more [tags] Pharmacy News [...]
  
  
• Vertex Incivek receives FDA approval for treatment of chronic hepatitis C (0)
  The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa [...]